Beacon Therapeutics

Beacon Therapeutics is a clinical-stage ophthalmic gene therapy company founded in 2023, dedicated to saving and restoring vision for patients with retinal diseases that can lead to blindness.

The company specializes in developing adeno-associated virus (AAV) gene therapies to deliver therapeutic proteins directly to the retina. Headquartered in Alachua, Florida, with additional offices in London and Cambridge, Beacon has raised approximately $367 million to support its clinical trials. The company's pipeline includes AGTC-501, a late-stage candidate for treating X-linked Retinitis Pigmentosa (XLRP), currently in Phase II clinical trials. Additionally, Beacon is developing therapies for Cone-Rod Dystrophy (CRD) and Dry Age-Related Macular Degeneration (dAMD), both in preclinical stages. Beacon Therapeutics serves patients in the UK and the US, focusing on those affected by rare and prevalent ocular diseases. The company operates on a B2G business model, partnering with healthcare systems and public health entities to advance its mission.